Vividion announces publication on discovery and preclinical study of small molecules activating KEAP1 via a covalent molecular glue to degrade NRF2.

Caloric restriction (CR) is the most potent intervention known to both protect against carcinogenesis and extend lifespan in laboratory animals. A variety of anticarcinogens and CR mimetics induce and ...

SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the U.S.

-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, ...

The screening of breast cancer awareness and health behaviors of women age 40 to 69 in Mus, the least developed city in Turkey: A population based, cross-sectional study. This is an ASCO Meeting ...

Research published today in the Journal of Hepatology suggests that the protein responsible for antioxidant defenses in humans may adversely affect the liver. The research was led by postdoctoral ...

Researchers have shown that inhibiting a key metabolic enzyme selectively kills melanoma cells and stops tumor growth. The findings could lead to a new class of drugs to selectively treat melanoma, ...

Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation SOUTH SAN FRANCISCO, Calif., Oct.